Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Regencell Bioscience Holdings Ltd (RGC)

Regencell Bioscience Holdings Ltd (RGC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,185
  • Shares Outstanding, K 13,013
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,870 K
  • 60-Month Beta -0.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.31
Trade RGC with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/17
See More
  • Average Estimate 0.34
  • Number of Estimates 6
  • High Estimate 0.39
  • Low Estimate 0.30
  • Prior Year 0.33
  • Growth Rate Est. (year over year) +3.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.50 unch
on 03/18/24
7.80 -42.29%
on 02/20/24
-3.50 (-43.75%)
since 02/16/24
3-Month
4.50 unch
on 03/18/24
10.50 -57.14%
on 12/29/23
-5.24 (-53.80%)
since 12/15/23
52-Week
4.50 unch
on 03/18/24
31.30 -85.62%
on 04/20/23
-22.40 (-83.27%)
since 03/16/23

Most Recent Stories

More News
Regencell Bioscience’s Standardized Formulae Are Shown to Reduce ADHD and ASD Symptoms in the Interim Results of its Second Efficacy Trial

Regencell Bioscience Holdings Limited (Nasdaq: RGC) (“ Regencell ”) today announced its interim results from its second efficacy trial.

RGC : 4.50 (-2.70%)
Regencell Bioscience Announces Additional EARTH Efficacy Trial Results Corroborating Effectiveness of its Investigational Liquid-Formula RGC-COV19TM in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-Day Treatment Period

Regencell Bioscience Holdings Limited (NASDAQ: RGC):

RGC : 4.50 (-2.70%)
Regencell Bioscience Holdings Limited Announces Over $5 Million Ordinary Share Purchases by CEO

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focusing on the research, development and commercialization of Traditional...

RGC : 4.50 (-2.70%)
Notable Two Hundred Day Moving Average Cross - RGC

In trading on Wednesday, shares of Regencell Bioscience Holdings Ltd crossed below their 200 day moving average of $24.46, changing hands as low as $23.60 per share. Regencell Bioscience Holdings Ltd...

RGC : 4.50 (-2.70%)
Regencell Bioscience Holdings Enters Oversold Territory (RGC)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

RGC : 4.50 (-2.70%)
Regencell Describes Their Traditional Chinese Medicine ("TCM") Treatments and Recent Efficacy Trial Results in New Video Interview on SNN Network

LOS ANGELES, CA / ACCESSWIRE / March 1, 2022 / SNN Network, The Official Small-, Micro- and Nano-Cap News Source™, today published a new Video Interview with the team from Regencell Bioscience Holdings...

RGC : 4.50 (-2.70%)
Regencell Bioscience’s Investigational Liquid-Formula RGC-COV19TM Shows Effectiveness Through Its Enrolled Patients in Eliminating Mild to Moderate COVID-19 Symptoms within the 6-day Treatment Period in its EARTH Efficacy Trial

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“ Regencell ” or the “ Company ”) today announced the results from an analysis of a total of 37 individuals enrolled in its E valuation and...

RGC : 4.50 (-2.70%)
Regencell Bioscience Holdings Limited Appoints Dr. William Wing-Yan Lo, JP to its Board of Directors

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment...

RGC : 4.50 (-2.70%)
Regencell Bioscience Holdings Limited Announces Over $1 Million Ordinary Share Purchase by CEO

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment...

RGC : 4.50 (-2.70%)
Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index

Regencell Bioscience Holdings Limited (NASDAQ: RGC) (“Regencell” or the “Company”), an early-stage bioscience company focuses on the research, development and commercialization of TCM for the treatment...

RGC : 4.50 (-2.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Regencell Bioscience Holdings Limited is an early-stage bioscience company which focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum...

See More

Key Turning Points

3rd Resistance Point 4.60
2nd Resistance Point 4.58
1st Resistance Point 4.54
Last Price 4.50
1st Support Level 4.48
2nd Support Level 4.46
3rd Support Level 4.42

See More

52-Week High 31.30
Fibonacci 61.8% 21.06
Fibonacci 50% 17.90
Fibonacci 38.2% 14.74
Last Price 4.50
52-Week Low 4.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar